癌症定制疫苗首度闖過III期
Merck與Moderna宣布，個性化腫瘤疫苗intismeran autogene在黑色素瘤III期試驗中取得陽性結果，與PD-1抑制劑聯用可顯著改善無復發生存期及無遠處轉移生存期。該療法利用患者腫瘤突變資料與AI篩選新生抗原，為每位患者製作專屬mRNA疫苗。
Search
5 results on this page
AI-Powered Personalized mRNA Cancer Vaccines Advance
Moderna and Merck reported that a personalized mRNA therapy, intismeran, combined with Keytruda met key recurrence and distant-metastasis survival endpoints in a prespecified interim analysis. The approach uses AI to select up to 34 tumor-specific neoantigens for an individually manufactured treatment.
Personalized mRNA Cancer Vaccine Clears Phase 3 Hurdle
Moderna and Merck reported positive Phase 3 results for personalized mRNA cancer vaccine mRNA-4157 combined with pembrolizumab in high-risk melanoma after surgery. The treatment significantly improved recurrence-free and distant metastasis-free survival versus pembrolizumab alone, though detailed data and overall survival results are still pending.
AI Explanations Can Weaken Human Judgment
A study found that LLM recommendations could persuade evaluators to reject promising innovations or approve weak ones. Providing narrative explanations made participants more likely to follow incorrect AI decisions, while unexplained recommendations led to better independent judgment.
Cancer AI’s Real Bottleneck Is Data
The article argues that AI is still far from curing cancer, with data quality and availability identified as the central obstacle. An unnamed startup believes better cancer datasets are essential for meaningful progress.
Page 1